Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.

A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.

Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.